[ Price : $8.95]
FDA will give priority review with a decision expected this year on a Pfizer BLA for elranatamab to treat some multiple myelomas.[ Price : $8.95]
FDA expands its warning against using specific artificial tears products to now include Delsam Pharmas Artificial Eye Ointment due...[ Price : $8.95]
FDA clears a RapidAI 510(k) for Rapid RV/LV, a tool for physicians to quickly assess the ratio between the right ventricle and the...[ Price : $8.95]
The U.S. Supreme Court declines to hear a Johnson & Johnson case that sought the high courts review and reversal of a California C...[ Price : $8.95]
Federal Register notice: FDA announces a 4/25 public meeting entitled Patient-Focused Drug Development for Long Covid.[ Price : $8.95]
FDA accepts for priority review a Regeneron BLA for pozelimab to treat CHAPLE disease in children and adults.[ Price : $8.95]
FDA says Office of New Drugs director Peter Stein will decide an Akebia Therapeutics formal dispute resolution request over the co...[ Price : $8.95]
FDA extends to 5/22 the PDUFA priority review action date for Astellas fezolinetant to treat some menopausal vasomotor symptoms.